Senno Therapeutics

Based in Tokyo, Japan, Senno Therapeutics Inc. develops innovative cell therapies targeting severe liver failure, utilizing advanced iPSC technology to create potential therapeutic solutions for patients in need. Senno Therapeutics specializes in advanced cell therapy development for severe liver conditions. Founded in 2024 in Tokyo, Japan, the company has engaged in one notable deal to date, culminating in an investment round on April 14, 2026.

The company’s operations are rooted in research at the University of Tokyo's Institute of Medical Science, aiming to address unmet needs in liver failure treatment. Senno Therapeutics specializes in the development of innovative cell therapies targeting severe liver failure, utilizing human induced pluripotent stem cell (iPSC) technology to produce liver progenitor cells and liver organoids. These core products serve as potential therapeutic solutions for patients awaiting liver transplants, addressing a critical unmet need in acute and chronic liver failure cases. The company's technologies were developed based on a decade of research at the University of Tokyo's Institute of Medical Science, and they aim to facilitate less invasive, early intervention treatments for liver disease patients.

Their offerings are positioned primarily within the Japanese healthcare market, although potential applications and collaborations may extend to international markets where there is a demand for advanced liver disease therapies. Senno Therapeutics generates revenue through strategic partnerships and collaborations within the biopharmaceutical sector, leveraging its proprietary technology to develop advanced cell-based therapies. The company engages with healthcare institutions, research organizations, and pharmaceutical companies interested in innovative treatment solutions for liver diseases. Revenue transactions typically occur through collaborative agreements, which may involve co-development or licensing of therapeutic technologies and products.

Specific pricing structures for their services and products, while not publicly detailed, would likely be contingent on the terms of individual partnerships, including milestones achieved in the development process and the commercialization of their cell therapy solutions. In April 2026, Senno Therapeutics, Inc. raised an undisclosed amount in venture funding led by returning investor Saisei Ventures, with participation from new investors One Capital and Mizuho Capital. This investment supports the company's advancement of non-clinical development and preparation for clinical trials of its lead cell therapy program.

Future growth plans include designing new products aimed at improving treatment options for liver diseases, with strategic expansions targeted towards international markets by 2027.